메뉴 건너뛰기




Volumn 66, Issue 3, 2013, Pages 159-168

Population pharmacokinetics of itraconazole in Japanese patients with invasive fungal peritonitis

Author keywords

[No Author keywords available]

Indexed keywords

ITRACONAZOLE;

EID: 84880530315     PISSN: 03682781     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (3)

References (19)
  • 1
    • 84865137044 scopus 로고    scopus 로고
    • Clinical efficacy and safety of intravenous itraconazole in the management of invasive candidiasis in patients of surgery and critical care
    • TAKESUE, Y.; S. ODA, S. FUJISHIMA, et al.: Clinical efficacy and safety of intravenous itraconazole in the management of invasive candidiasis in patients of surgery and critical care. J. Infect. Chemother. 18: 515-521, 2012
    • (2012) J. Infect. Chemother. , vol.18 , pp. 515-521
    • Takesue, Y.1    Oda, S.2    Fujishima, S.3
  • 2
    • 0031952586 scopus 로고    scopus 로고
    • Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men
    • CRAIG, W. A.: Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26: 1-12, 1998
    • (1998) Clin. Infect. Dis. , vol.26 , pp. 1-12
    • Craig, W.A.1
  • 3
    • 0031966359 scopus 로고    scopus 로고
    • Pharmacodynamics of fluconazole in a murine model of systemic candidiasis
    • LOUIE, A.; G. L. DRUSANO, P. BANERJEE, et al.: Pharmacodynamics of fluconazole in a murine model of systemic candidiasis. Antimicrob. Agents Chemother. 42: 1105-1109, 1998
    • (1998) Antimicrob. Agents Chemother. , vol.42 , pp. 1105-1109
    • Louie, A.1    Drusano, G.L.2    Banerjee, P.3
  • 4
    • 0032828929 scopus 로고    scopus 로고
    • Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine model of disseminated candidiasis infection model
    • ANDES, D. & M. VAN OGTROP: Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine model of disseminated candidiasis infection model. Antimicrob. Agents Chemother. 43: 2116-2120, 1999
    • (1999) Antimicrob. Agents Chemother. , vol.43 , pp. 2116-2120
    • Andes, D.1    Van Ogtrop, M.2
  • 5
    • 0034063522 scopus 로고    scopus 로고
    • In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model
    • ANDES, D. & M. VAN OGTROP: In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model. Antimicrob. Agents Chemother. 44: 938-942, 2000
    • (2000) Antimicrob. Agents Chemother. , vol.44 , pp. 938-942
    • Andes, D.1    Van Ogtrop, M.2
  • 6
    • 0035115021 scopus 로고    scopus 로고
    • Pharmacodynamics of amphotericine B in a neutropenic-mouse disseminated candidiasis model
    • ANDES, D.; T. STAMSTED & R. CONKLIN: Pharmacodynamics of amphotericine B in a neutropenic-mouse disseminated candidiasis model. Antimicrob. Agents Chemother. 45: 922-926, 2001
    • (2001) Antimicrob. Agents Chemother. , vol.45 , pp. 922-926
    • Andes, D.1    Stamsted, T.2    Conklin, R.3
  • 7
    • 0037377996 scopus 로고    scopus 로고
    • In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model
    • ANDES, D.; K. MARCHILLO, J. LOWTHER, et al.: In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model. Antimicrob. Agents Chemother. 47: 1187-1192, 2003
    • (2003) Antimicrob. Agents Chemother. , vol.47 , pp. 1187-1192
    • Andes, D.1    Marchillo, K.2    Lowther, J.3
  • 8
    • 0141925590 scopus 로고    scopus 로고
    • In vivo pharmacodynamics of a new triazole, ravuconazole, in a murine candidiasis model
    • ANDES, D.; K. MARCHILLO, T. STAMSTAD, et al.: In vivo pharmacodynamics of a new triazole, ravuconazole, in a murine candidiasis model. Antimicrob. Agents Chemother. 47: 3165-3169, 2003
    • (2003) Antimicrob. Agents Chemother. , vol.47 , pp. 3165-3169
    • Andes, D.1    Marchillo, K.2    Stamstad, T.3
  • 9
    • 79955902959 scopus 로고    scopus 로고
    • Pharmacokinetic-pharmacodynamic study of itraconazole in patients with fungal infections in intensive care units
    • HAGIHARA, M.; H. KASAI, T. UMEMURA, et al.: Pharmacokinetic- pharmacodynamic study of itraconazole in patients with fungal infections in intensive care units. J. Infect. Chemother. 17: 224-230, 2011
    • (2011) J. Infect. Chemother. , vol.17 , pp. 224-230
    • Hagihara, M.1    Kasai, H.2    Umemura, T.3
  • 10
    • 0024319962 scopus 로고
    • Treatment of invasive aspergillosis with itraconazole
    • DENNING, D. W.; R. M. TUCKER, L. H. HANSON, et al.: Treatment of invasive aspergillosis with itraconazole. Am. J. Med. 86: 791-800, 1989
    • (1989) Am. J. Med. , vol.86 , pp. 791-800
    • Denning, D.W.1    Tucker, R.M.2    Hanson, L.H.3
  • 12
    • 0033846298 scopus 로고    scopus 로고
    • Prophylaxis and treatment of fungal infections associated with haematological malignancies
    • ASCIOGLU, S.; B. E. DE PAUW & J. F. MEIS: Prophylaxis and treatment of fungal infections associated with haematological malignancies. Int. J. Antimicrob. Agents 15: 159-168, 2000
    • (2000) Int. J. Antimicrob. Agents , vol.15 , pp. 159-168
    • Ascioglu, S.1    De Pauw, B.E.2    Meis, J.F.3
  • 13
    • 33745755772 scopus 로고    scopus 로고
    • A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients
    • OREN, I,; J. M. ROWE, H. SPRECHER, et al.: A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 38: 127-134, 2006
    • (2006) Bone Marrow Transplant , vol.38 , pp. 127-134
    • Oren, I.1    Rowe, J.M.2    Sprecher, H.3
  • 15
    • 0030953226 scopus 로고    scopus 로고
    • Stability and performance of a population pharmacokinetic model
    • ETTE, E. I.: Stability and performance of a population pharmacokinetic model. J. Clin. Pharmacol. 37: 486-495, 1997
    • (1997) J. Clin. Pharmacol. , vol.37 , pp. 486-495
    • Ette, E.I.1
  • 16
    • 84865139559 scopus 로고    scopus 로고
    • Edited be the Committee for the Preparation of Gudelines regarding Deep Mycosis. Tokyo, Kyowa Kikaku
    • Guidelines for the Diagnosis/Treatment of Deep Mycosis in 2007. Edited be the Committee for the Preparation of Gudelines regarding Deep Mycosis. Tokyo, Kyowa Kikaku, 2007
    • (2007) Guidelines for the Diagnosis/Treatment of Deep Mycosis in 2007
  • 18
    • 0017204845 scopus 로고
    • Pharmacokinetics of dosing regimens which use multiple intravenous infusions: Gentamicin in burn patients
    • SAWCHUK, R. J. & D. E. ZASKE: Pharmacokinetics of dosing regimens which use multiple intravenous infusions: gentamicin in burn patients. J. Pharmacokinet. Biopharm. 4: 183-195, 1976
    • (1976) J. Pharmacokinet. Biopharm. , vol.4 , pp. 183-195
    • Sawchuk, R.J.1    Zaske, D.E.2
  • 19
    • 77649204506 scopus 로고    scopus 로고
    • Antifungal susceptibility against Candida species isolated from patient with invasive fungal peritonitis and investigation on clinical breakpoints of itraconazole
    • YAMAGISHI, Y.; M. TERADA, E. OHKI, et al.: Antifungal susceptibility against Candida species isolated from patient with invasive fungal peritonitis and investigation on clinical breakpoints of itraconazole. Jpn. J. Antibiotics 62: 415-434, 2009
    • (2009) Jpn. J. Antibiotics , vol.62 , pp. 415-434
    • Yamagishi, Y.1    Terada, M.2    Ohki, E.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.